Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Vixiar Medical, Inc
- Proposal award date
- 2017-09-01
- Contract end date
- 2019-03-31
- UEI
- NEJREN5KEXT4
- Solicitation number
- PA16-303
- Topic code
- NHLBI
Research abstract
Congestive heart failure CHF is the most common reason for hospitalization in the U S with over million
admissions per year Patients admitted with CHF usually need IV diuretics to promote fluid removal The
readmission rate is high over by days and by days post discharge This also presents an
enormous economic burden hospitalizations account for a large percentage of the $ billion spent yearly on
heart failure One of the reasons for the high readmission rate is that it can be very challenging to detect
elevated cardiac filling pressure until symptoms recur that prompt a return to the hospital There is much
enthusiasm for the potential of remote noninvasive monitoring to predict and reduce heart failure readmissions
but daily weights vital signs and symptoms have limited sensitivity and specificity or are later indicators We
have developed the first device for assessing cardiac filling pressure noninvasively that can be used at home
It records finger photoplethysmography ppg continuously while also guiding and recording a standardized
Valsalva maneuver into an expiratory pressure transducer The latest prototype is hand held battery powered
and communicates wirelessly with an iPad capable of remote transmission The device is easy to use employs
technology that is robust and inexpensive and testing takes only minutes We have shown that the output
measure correlates with the invasive gold standard measures of left heart filling pressure left ventricular end
diastolic pressure LVEDP and pulmonary capillary wedge pressure PCWP More importantly we have
shown that it identifies clinically meaningful categories of elevated LVEDP and PCWP Most recently we have
shown that LVEDP derived from the device on the day of discharge has high specificity for predicting heart
failure readmission need for outpatient IV diuresis or death within days after discharge Sensitivity and
specificity for predicting readmission may be improved by following LVEDP over time at home In this Fast
Track project we intend in Phase I to develop further the automated waveform analysis algorithms remote
transmission capabilities and prototyping necessary to conduct a home based observational clinical study In
the clinical study in Phase II post discharge heart failure patients will test themselves at home twice a day for
up to days and the data will be transmitted remotely We will determine if LVEDP obtained twice daily
predicts heart failure events a combination of heart failure readmission need for outpatient IV diuresis or
death within days after discharge Our team has extensive combined expertise in waveform analysis
software development medical device prototyping project engineering heart failure clinical investigation and
prior success in medical device start ups If the outcome of our observational clinical study is successful the
next step would be to conduct a multi center interventional trial to determine if guiding therapy based on daily
device testing reduces post discharge heart failure events The device has the potential to improve quality of
life reduce health care costs and improve survival in patients with heart failure Congestive heart failure is the most common reason for hospitalization and the readmission
rate is high which is a substantial health and cost burden We have developed a noninvasive
test for detecting congestion before symptoms develop that may reduce re hospitalizations
reduce health care cost and improve quality of life in patients with heart failure We will
determine in patients testing themselves each day at home after a hospital discharge how well
the device predicts readmissions for heart failure
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
2 SBIR/STTR records share this UEI (2017–2019). Reported award amounts total $1,317,639. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards